<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876187</url>
  </required_header>
  <id_info>
    <org_study_id>A4091012</org_study_id>
    <secondary_id>CLBP-IV PH2B</secondary_id>
    <nct_id>NCT00876187</nct_id>
  </id_info>
  <brief_title>A Study of Tanezumab in Adults With Chronic Low Back Pain</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, ACTIVE- AND PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP STUDY OF THE ANALGESIC EFFECTS OF TANEZUMAB IN ADULT PATIENTS WITH CHRONIC LOW BACK PAIN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of multiple doses of&#xD;
      tanezumab administered every 8 weeks in treating chronic low back pain. Tanezumab is a&#xD;
      monoclonal antibody directed against human nerve growth factor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2009</start_date>
  <completion_date type="Actual">February 1, 2011</completion_date>
  <primary_completion_date type="Actual">June 16, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 16: Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Overall possible score range for daily average LBPI at specified visit was 0= no pain to 10= worst possible pain, where higher scores indicated higher pain intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
    <description>RMDQ: back-specific, participant administered questionnaire that assesses how well participants with low back pain were able to function with regard to daily activities. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement if it describes his/her functional ability on the day of assessment. The number of statements marked are added up by the clinician. Total RMDQ score is calculated as the sum of number of statements marked. Total possible RMDQ score: 0 (best functioning) to 24 (worst functioning), with higher scores indicated greater disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment (PGA) of Low Back Pain Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
    <description>Participants answered: &quot;Considering all ways your low back pain affects you, how are you doing today?&quot; Participants rated their condition using scale assessing symptoms and limitations to carry out normal daily activities. Score range:1 to 5. 1: Very Good (No symptoms and limitations); 2: Good (Mild symptoms and no limitations); 3: Fair (Moderate symptoms and some limitations); 4: Poor (Severe symptoms and inability to carry out most activities); 5: Very Poor (Very severe, intolerable symptoms and inability to carry all activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12</time_frame>
    <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cumulative Reduction From Baseline at Week 16 in Daily Average Low Back Pain Intensity (LBPI) Score : Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Participants with specified reduction (as percent) from baseline at Week 16 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least 30 Percent (%) and 50% Reduction From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
    <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Worst and Average Pain at Week 2, 4, 8, 12, 16: Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
    <description>BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure level of interference of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes). Results are reported for worst and average pain, each with a score range: 0 (no pain) and 10 (pain as bad as you can imagine), higher scores indicated worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Pain Interference Index, Pain Interference Score for General Activity, Walking Ability, Sleep and Normal Work at Week 2, 4, 8, 12 and 16: BOCF</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
    <description>BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure pain interference (PI) on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes); higher score = greater impairment. The 7 items in Q5 averaged to obtain pain interference index (function composite score), range: 0 (no interference) to 10 (complete interference); higher score = greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation Due to Lack of Efficacy</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic Low Back Pain (CLBP) Responder Index: Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Week 2, 4, 8, 12, 16</time_frame>
    <description>Chronic Low Back Pain (CLBP) Responder Index: A response was defined as reduction of at least 30% in mean daily average LBPI from baseline to a specified week, decrease of at least 30% in PGA of low back pain from baseline to the specified week and no worsening (increase) in RMDQ total score from baseline to the specified week. Participants who were responders were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) at Week 8 and 16</measure>
    <time_frame>Baseline, Week 8, 16</time_frame>
    <description>WPAI:SHP is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Four scores are derived as percent: activity impairment (AI), impairment while working (IW), overall work impairment (OWI), work time missed (WTM). Each of 4 scores expressed as impairment percentages with a total possible score range of 0 to 100, high percentage= more impairment, less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Used Rescue Medications</measure>
    <time_frame>Week 2, 4, 8, 12, 16</time_frame>
    <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Rescue Medication Use</measure>
    <time_frame>Week 2, 4, 8, 12, 16</time_frame>
    <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Rescue Medication Taken</measure>
    <time_frame>Week 2, 4, 8, 12, 16</time_frame>
    <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Neuropathy Impairment Score (NIS) at Week 8, 16 and 24</measure>
    <time_frame>Baseline, Week 8, 16, 24</time_frame>
    <description>NIS is a standardized instrument used to evaluate signs of peripheral neuropathy in participants. NIS is the sum of scores of 37 items, from both the left and right side of following 4 domains: cranial nerves (5 items), muscle weakness (19 items), reflexes (5 items) and sensation (8 items). Each of 24 items related to cranial nerves and muscle weakness, scored from 0 (normal) to 4 (paralysis); higher scores indicated higher abnormality/impairment. Each of 13 items related to reflexes and sensation, scored as 0 (normal), 1 (decreased) and 2 (absent); higher scores indicated lesser reflexes and sensation. For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Anti-Tanezumab Antibodies</measure>
    <time_frame>Baseline (Day 1), Week 8, 16, 24</time_frame>
    <description>Human serum anti-drug antibody (ADA) samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative enzyme-linked immunosorbent assay (ELISA). Same participant may have positive ADA result at more than 1 time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Tanezumab</measure>
    <time_frame>Baseline (pre-dose and 1 hour [hr] post-dose); Any time point at Week 4 Visit; Week 8 (pre-dose and 1 hr post-dose); Any time point at Week 16 Visit, at Week 24 Visit</time_frame>
    <description>Analysis was done by setting concentration values below the lower limit of quantification (LLOQ) to zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Nerve Growth Factor (NGF) Concentration</measure>
    <time_frame>Baseline (pre-dose and 1 hour [hr] post-dose); Any time point at Week 4 Visit; Week 8 (pre-dose and 1 hr post-dose); Any time point at Week 16 Visit, at Week 24 Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 24 that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1359</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Tanezumab 20 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 10 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 5 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tanezumab 20 mg IV</intervention_name>
    <description>2 IV administrations of tanezumab 20 mg at an 8 week interval</description>
    <arm_group_label>Tanezumab 20 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for naproxen</intervention_name>
    <description>Oral placebo for naproxen twice a day for 16 weeks</description>
    <arm_group_label>Tanezumab 20 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tanezumab 10 mg IV</intervention_name>
    <description>2 IV administrations of tanezumab 10 mg at an 8 week interval</description>
    <arm_group_label>Tanezumab 10 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for naproxen</intervention_name>
    <description>Oral placebo for naproxen twice a day for 16 weeks</description>
    <arm_group_label>Tanezumab 10 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tanezumab 5 mg IV</intervention_name>
    <description>2 IV administrations of tanezumab 5 mg at an 8 week interval</description>
    <arm_group_label>Tanezumab 5 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for naproxen</intervention_name>
    <description>Oral placebo for naproxen twice a day for 16 weeks</description>
    <arm_group_label>Tanezumab 5 mg IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for tanezumab</intervention_name>
    <description>2 IV administrations of placebo for tanezumab at an 8 week interval</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Oral naproxen 500 mg twice a day for 16 weeks</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for tanezumab</intervention_name>
    <description>2 IV administrations of placebo for tanezumab at an 8 week interval</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for naproxen</intervention_name>
    <description>Oral placebo for naproxen twice a day for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Present with duration of low back pain of ≥3 months requiring regular use of analgesic&#xD;
             medication (&gt;4 days per week for the past month). Analgesic medication may consist of&#xD;
             NSAIDs, selective COX-2 inhibitors, immediate release opioids, or combinations, with&#xD;
             certain protocol-defined limitations.&#xD;
&#xD;
          -  Primary location of low back pain must be between the 12th thoracic vertebra and the&#xD;
             lower gluteal folds, with or without radiation into the posterior thigh&#xD;
&#xD;
          -  Must meet criteria for pain severity and global assessment of low back pain at&#xD;
             Screening and Baseline visits&#xD;
&#xD;
          -  Female patients of child-bearing potential (and male patients with female partners who&#xD;
             are of child-bearing potential) must use 2 methods of contraception throughout the&#xD;
             study&#xD;
&#xD;
          -  Patients must be willing to discontinue all pain medications for chronic low back pain&#xD;
             except rescue medication and not use prohibited pain medications throughout the&#xD;
             duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of lumbosacral radiculopathy within the past 2 years.&#xD;
&#xD;
          -  Back pain due to visceral disorder (eg, endometriosis).&#xD;
&#xD;
          -  Back pain due to major trauma or osteoporotic compression fracture in the past 6&#xD;
             months.&#xD;
&#xD;
          -  History of rheumatoid arthritis, seronegative spondyloarthropathy, Paget's disease of&#xD;
             spine, pelvis or femur; fibromyalgia; tumors or infections of the spinal cord.&#xD;
&#xD;
          -  Surgical intervention during the past 6 months for the treatment of low back pain or&#xD;
             plans for surgical intervention during the course of the study.&#xD;
&#xD;
          -  Current or pending worker's compensation, litigation, disability, or any other&#xD;
             monetary settlement regarding his/her CLBP or any other pain condition, or any closed&#xD;
             claim within the past 5 years.&#xD;
&#xD;
          -  Use of any analgesic or muscle relaxant within 48 hours prior to the five days before&#xD;
             Baseline&#xD;
&#xD;
          -  Patients receiving only acetaminophen, gabapentin or pregabalin to manage their&#xD;
             chronic low back pain.&#xD;
&#xD;
          -  Patients taking &gt;325 mg/day of aspirin.&#xD;
&#xD;
          -  Use of any antidepressants with the exception of stable treatment with selective&#xD;
             serotonin reuptake inhibitors (SSRIs).&#xD;
&#xD;
          -  Use of any sedatives/hypnotics, anxiolytics, tranquilizers, or benzodiazepines unless&#xD;
             daily dose has been stable and will remain unchanged throughout the study period.&#xD;
&#xD;
          -  Systemic corticosteroid therapy within 30 days (inhaled and topical corticosteroids&#xD;
             are permitted).&#xD;
&#xD;
          -  Local or epidural injection of corticosteroids, as well as injections of&#xD;
             corticosteroids in the back within 3 months.&#xD;
&#xD;
          -  Botulinum toxin (Botox®) injection for chronic low back pain within 4 months.&#xD;
&#xD;
          -  Requirement for new, concomitant physiotherapy including, but not limited to,&#xD;
             transdermal electroneural stimulation (TENS), massage or spinal manipulation for the&#xD;
             duration of the study period.&#xD;
&#xD;
          -  Active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration&#xD;
             within 3 months, or any history of gastrointestinal bleeding.&#xD;
&#xD;
          -  Current use of lithium or anticoagulant agents.&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to NSAIDs; history of asthma, urticaria, or&#xD;
             allergic type reactions after taking aspirin or NSAIDs.&#xD;
&#xD;
          -  Inflammatory bowel disease, a chronic or acute renal or hepatic disorder, a&#xD;
             significant coagulation defect, or other condition that might preclude the use of an&#xD;
             NSAID.&#xD;
&#xD;
          -  History of intolerance to acetaminophen or paracetamol or any of its excipients.&#xD;
&#xD;
          -  History of known alcohol, analgesic or narcotic abuse within 2 years.&#xD;
&#xD;
          -  Presence of drugs of abuse (including prescription medications without a valid&#xD;
             prescription), other illegal drugs or marijuana in the urine toxicology screen&#xD;
             obtained at Screening.&#xD;
&#xD;
          -  History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal&#xD;
             antibody or IgG fusion protein.&#xD;
&#xD;
          -  Use of biologics other than study medication, including any live vaccines, within 3&#xD;
             months, or use during the study (intranasal Flumist® vaccine is an exception).&#xD;
&#xD;
          -  Signs and symptoms of clinically significant cardiac disease.&#xD;
&#xD;
          -  Diagnosis of a transient ischemic attack within the 6 months, or residual deficits&#xD;
             from stroke that would preclude completion of required study activities.&#xD;
&#xD;
          -  History of cancer within 5 years.&#xD;
&#xD;
          -  Use of any investigational medication within 30 days (3 months for investigational&#xD;
             biologics).&#xD;
&#xD;
          -  Expected to undergo a therapeutic procedure or to use any analgesic other than those&#xD;
             specified in the protocol throughout the study period.&#xD;
&#xD;
          -  Previous exposure to exogenous NGF or to an anti NGF antibody.&#xD;
&#xD;
          -  Screening laboratory results and blood pressure within specified limits.&#xD;
&#xD;
          -  Positive Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) tests at&#xD;
             screening.&#xD;
&#xD;
          -  History, diagnosis, or signs and symptoms of clinically significant neurological&#xD;
             disease.&#xD;
&#xD;
          -  History, diagnosis, signs or symptoms of any clinically significant psychiatric&#xD;
             disorder.&#xD;
&#xD;
          -  Hospital admission for depression or suicide attempt within 5 years or active, severe&#xD;
             major depression at Screening.&#xD;
&#xD;
          -  Likelihood of being non compliant with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Research Group LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simon Williamson Clinic, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simon-Williamson Clinic, PC</name>
      <address>
        <city>Hueytown</city>
        <state>Alabama</state>
        <zip>35023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saadat Ansari, MD office</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Phoenix Southeast</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pivotal Research Centers</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.: Scottsdale, AZ</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Phamaceutical Research, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Clinical Research, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Family Practice Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, Inc</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samaritan Center for Medical Research Medical Group</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North County Clinical Research (NCCR)</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances in Medicine</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Control Research, Inc</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials of Sacramento, Inc.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wetlin Research Associates, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology &amp; Osteoporosis Medical Group, Inc.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicos, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stamford Therapeutics Consortium</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates, LLC</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research, LLC</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Medical Center of Walton County</name>
      <address>
        <city>DeFuniak Springs</city>
        <state>Florida</state>
        <zip>32435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SJS Clinical Research, Inc.</name>
      <address>
        <city>Destin</city>
        <state>Florida</state>
        <zip>32541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRIA Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research, LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collier Neurologic Specialists</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Incorporated</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Clinical Research Center</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dale G. Bramlet, MD</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthntis &amp; Rheumatic Care Center</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Prospective Outcome Studies</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River Birch Research Alliance, LLC</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drug Studies America</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selah Medical Center, PA</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSphere Medical Research Center, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overiand Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Technology, Inc.</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Association, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Biomedical Research, LLC</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Diabetes Clinic</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter A. Holt, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCM Medical Services</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Trials</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician's Surgery Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medex Healthcare Research, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest/ A Division of Banyan Group, Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mirkil Medical</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research of America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central New York Clinical Research</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medex Healthcare Research, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medex Healthcare Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Research Network, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmquest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northstate Clinical Research, PLLC</name>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <zip>28645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christine Codding, MD</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBride Clinic</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunstone Medical Research, LLC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon), Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Pain Management</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Associates, PC</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Clinical Research</name>
      <address>
        <city>Bridgeville</city>
        <state>Pennsylvania</state>
        <zip>15017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Center for Clinical Research</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Arthritis Center, P.A.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Orthopaedic Sports Medicine</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI Research Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolf River Medical Group, LLC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Therapeutics, Inc.</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson City Internal Medicine</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Medical Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter F. Chase, MD, PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DiscoveResearch, Inc.</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DiscoveResearch, Incorporated</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Hypertension &amp; Metabolic Research Institute Punzi Medical Center</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRK Medical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances In Health, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Research</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Theresia Lee, MD</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paragon Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121-6924</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Norfolk, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research, Incorporated</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Pain Management</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091012&amp;StudyName=A%20Study%20of%20Tanezumab%20in%20Adults%20with%20Chronic%20Low%20Back%20Pain</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2021</results_first_posted>
  <disposition_first_submitted>July 19, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 19, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2011</disposition_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized controlled trial</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>nerve growth factor</keyword>
  <keyword>naproxen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Tanezumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants underwent for a 5-day initial pain assessment period prior to randomization.</recruitment_details>
      <pre_assignment_details>Participants who discontinued due to lack of efficacy or completed the treatment in this study were eligible to enroll in safety extension study A4091039 (NCT00924664).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="P2">
          <title>Tanezumab 5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="P3">
          <title>Tanezumab 10 mg</title>
          <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="P4">
          <title>Tanezumab 20 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="P5">
          <title>Naproxen 500 mg</title>
          <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="298"/>
                <participants group_id="P4" count="297"/>
                <participants group_id="P5" count="298"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="295"/>
                <participants group_id="P4" count="295"/>
                <participants group_id="P5" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="128">Participants who completed treatment at Week 16 visit.</participants>
                <participants group_id="P2" count="146">Participants who completed treatment at Week 16 visit.</participants>
                <participants group_id="P3" count="193">Participants who completed treatment at Week 16 visit.</participants>
                <participants group_id="P4" count="188">Participants who completed treatment at Week 16 visit.</participants>
                <participants group_id="P5" count="185">Participants who completed treatment at Week 16 visit.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="210"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="279"/>
                <participants group_id="P4" count="275"/>
                <participants group_id="P5" count="271"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entered extension study</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="151"/>
                <participants group_id="P5" count="144"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) analysis set included all participants who received at least 1 dose of intravenous study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="B2">
          <title>Tanezumab 5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="B3">
          <title>Tanezumab 10 mg</title>
          <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="B4">
          <title>Tanezumab 20 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="B5">
          <title>Naproxen 500 mg</title>
          <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="232"/>
            <count group_id="B3" value="295"/>
            <count group_id="B4" value="295"/>
            <count group_id="B5" value="295"/>
            <count group_id="B6" value="1347"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="13.2"/>
                    <measurement group_id="B2" value="51.5" spread="14.2"/>
                    <measurement group_id="B3" value="52.0" spread="13.9"/>
                    <measurement group_id="B4" value="51.2" spread="12.9"/>
                    <measurement group_id="B5" value="52.6" spread="13.2"/>
                    <measurement group_id="B6" value="51.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="157"/>
                    <measurement group_id="B4" value="165"/>
                    <measurement group_id="B5" value="152"/>
                    <measurement group_id="B6" value="714"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="143"/>
                    <measurement group_id="B6" value="633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 16: Baseline Observation Carried Forward (BOCF)</title>
        <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Overall possible score range for daily average LBPI at specified visit was 0= no pain to 10= worst possible pain, where higher scores indicated higher pain intensity.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 16: Baseline Observation Carried Forward (BOCF)</title>
          <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Overall possible score range for daily average LBPI at specified visit was 0= no pain to 10= worst possible pain, where higher scores indicated higher pain intensity.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.71" spread="1.37"/>
                    <measurement group_id="O2" value="6.62" spread="1.36"/>
                    <measurement group_id="O3" value="6.57" spread="1.39"/>
                    <measurement group_id="O4" value="6.74" spread="1.48"/>
                    <measurement group_id="O5" value="6.77" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="2.01"/>
                    <measurement group_id="O2" value="-1.55" spread="2.07"/>
                    <measurement group_id="O3" value="-2.02" spread="2.40"/>
                    <measurement group_id="O4" value="-2.19" spread="2.52"/>
                    <measurement group_id="O5" value="-1.70" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment difference and 95 percent (%) confidence interval (CI) was based on least squares (LS) mean. Analysis of Covariance (ANCOVA) was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.113</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.688</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</title>
        <description>RMDQ: back-specific, participant administered questionnaire that assesses how well participants with low back pain were able to function with regard to daily activities. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement if it describes his/her functional ability on the day of assessment. The number of statements marked are added up by the clinician. Total RMDQ score is calculated as the sum of number of statements marked. Total possible RMDQ score: 0 (best functioning) to 24 (worst functioning), with higher scores indicated greater disability.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</title>
          <description>RMDQ: back-specific, participant administered questionnaire that assesses how well participants with low back pain were able to function with regard to daily activities. The questionnaire consists of 24 statements and the participant is instructed to put a mark next to each appropriate statement if it describes his/her functional ability on the day of assessment. The number of statements marked are added up by the clinician. Total RMDQ score is calculated as the sum of number of statements marked. Total possible RMDQ score: 0 (best functioning) to 24 (worst functioning), with higher scores indicated greater disability.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.79" spread="4.74"/>
                    <measurement group_id="O2" value="12.24" spread="4.92"/>
                    <measurement group_id="O3" value="12.98" spread="5.11"/>
                    <measurement group_id="O4" value="13.00" spread="4.97"/>
                    <measurement group_id="O5" value="12.86" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="3.74"/>
                    <measurement group_id="O2" value="-2.47" spread="4.61"/>
                    <measurement group_id="O3" value="-2.59" spread="4.41"/>
                    <measurement group_id="O4" value="-2.39" spread="4.61"/>
                    <measurement group_id="O5" value="-2.28" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="4.04"/>
                    <measurement group_id="O2" value="-2.81" spread="4.52"/>
                    <measurement group_id="O3" value="-3.45" spread="4.90"/>
                    <measurement group_id="O4" value="-3.35" spread="4.87"/>
                    <measurement group_id="O5" value="-2.39" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="4.13"/>
                    <measurement group_id="O2" value="-2.62" spread="4.43"/>
                    <measurement group_id="O3" value="-2.93" spread="4.75"/>
                    <measurement group_id="O4" value="-3.47" spread="5.17"/>
                    <measurement group_id="O5" value="-2.27" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="4.13"/>
                    <measurement group_id="O2" value="-2.23" spread="3.82"/>
                    <measurement group_id="O3" value="-3.16" spread="4.97"/>
                    <measurement group_id="O4" value="-3.26" spread="4.81"/>
                    <measurement group_id="O5" value="-2.44" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="4.15"/>
                    <measurement group_id="O2" value="-2.27" spread="4.07"/>
                    <measurement group_id="O3" value="-3.20" spread="5.07"/>
                    <measurement group_id="O4" value="-2.82" spread="4.65"/>
                    <measurement group_id="O5" value="-2.08" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient's Global Assessment (PGA) of Low Back Pain Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</title>
        <description>Participants answered: &quot;Considering all ways your low back pain affects you, how are you doing today?&quot; Participants rated their condition using scale assessing symptoms and limitations to carry out normal daily activities. Score range:1 to 5. 1: Very Good (No symptoms and limitations); 2: Good (Mild symptoms and no limitations); 3: Fair (Moderate symptoms and some limitations); 4: Poor (Severe symptoms and inability to carry out most activities); 5: Very Poor (Very severe, intolerable symptoms and inability to carry all activities).</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Global Assessment (PGA) of Low Back Pain Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</title>
          <description>Participants answered: &quot;Considering all ways your low back pain affects you, how are you doing today?&quot; Participants rated their condition using scale assessing symptoms and limitations to carry out normal daily activities. Score range:1 to 5. 1: Very Good (No symptoms and limitations); 2: Good (Mild symptoms and no limitations); 3: Fair (Moderate symptoms and some limitations); 4: Poor (Severe symptoms and inability to carry out most activities); 5: Very Poor (Very severe, intolerable symptoms and inability to carry all activities).</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="294"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="0.58"/>
                    <measurement group_id="O2" value="3.41" spread="0.60"/>
                    <measurement group_id="O3" value="3.33" spread="0.56"/>
                    <measurement group_id="O4" value="3.36" spread="0.56"/>
                    <measurement group_id="O5" value="3.35" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.80"/>
                    <measurement group_id="O2" value="-0.62" spread="0.91"/>
                    <measurement group_id="O3" value="-0.66" spread="0.89"/>
                    <measurement group_id="O4" value="-0.62" spread="1.00"/>
                    <measurement group_id="O5" value="-0.59" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.88"/>
                    <measurement group_id="O2" value="-0.78" spread="0.89"/>
                    <measurement group_id="O3" value="-0.77" spread="0.90"/>
                    <measurement group_id="O4" value="-0.84" spread="0.95"/>
                    <measurement group_id="O5" value="-0.67" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.84"/>
                    <measurement group_id="O2" value="-0.66" spread="0.93"/>
                    <measurement group_id="O3" value="-0.71" spread="0.92"/>
                    <measurement group_id="O4" value="-0.78" spread="0.93"/>
                    <measurement group_id="O5" value="-0.54" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.82"/>
                    <measurement group_id="O2" value="-0.69" spread="0.91"/>
                    <measurement group_id="O3" value="-0.73" spread="0.90"/>
                    <measurement group_id="O4" value="-0.74" spread="0.98"/>
                    <measurement group_id="O5" value="-0.59" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.78"/>
                    <measurement group_id="O2" value="-0.59" spread="0.96"/>
                    <measurement group_id="O3" value="-0.63" spread="0.91"/>
                    <measurement group_id="O4" value="-0.67" spread="0.93"/>
                    <measurement group_id="O5" value="-0.49" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF)</title>
        <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF)</title>
          <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="1.84"/>
                    <measurement group_id="O2" value="-1.48" spread="1.79"/>
                    <measurement group_id="O3" value="-1.83" spread="1.89"/>
                    <measurement group_id="O4" value="-1.68" spread="2.19"/>
                    <measurement group_id="O5" value="-1.85" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="1.95"/>
                    <measurement group_id="O2" value="-1.94" spread="2.00"/>
                    <measurement group_id="O3" value="-2.47" spread="2.22"/>
                    <measurement group_id="O4" value="-2.44" spread="2.33"/>
                    <measurement group_id="O5" value="-2.05" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="2.05"/>
                    <measurement group_id="O2" value="-1.82" spread="1.99"/>
                    <measurement group_id="O3" value="-2.23" spread="2.25"/>
                    <measurement group_id="O4" value="-2.32" spread="2.40"/>
                    <measurement group_id="O5" value="-1.82" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="2.14"/>
                    <measurement group_id="O2" value="-1.92" spread="2.17"/>
                    <measurement group_id="O3" value="-2.27" spread="2.47"/>
                    <measurement group_id="O4" value="-2.37" spread="2.56"/>
                    <measurement group_id="O5" value="-1.93" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 2: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.221</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 2: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change at Week 2: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 2: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 2: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.703</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 2: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.379</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 4: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 4: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change at Week 4: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>-0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 4: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.862</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 4: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 4: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 8: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 8: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change at Week 8: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 8: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.668</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 8: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 8: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.773</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 12: Treatment difference and 95% CI was based on LS mean. ANCOVA was performed with treatment as main effects, baseline value as a covariate, and study site as a random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cumulative Reduction From Baseline at Week 16 in Daily Average Low Back Pain Intensity (LBPI) Score : Baseline Observation Carried Forward (BOCF)</title>
        <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Participants with specified reduction (as percent) from baseline at Week 16 are reported.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Reduction From Baseline at Week 16 in Daily Average Low Back Pain Intensity (LBPI) Score : Baseline Observation Carried Forward (BOCF)</title>
          <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit. Participants with specified reduction (as percent) from baseline at Week 16 are reported.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greater than (&gt;) 0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="171"/>
                    <measurement group_id="O4" value="174"/>
                    <measurement group_id="O5" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to (&gt;=)10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="159"/>
                    <measurement group_id="O4" value="162"/>
                    <measurement group_id="O5" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="136"/>
                    <measurement group_id="O4" value="145"/>
                    <measurement group_id="O5" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="123"/>
                    <measurement group_id="O4" value="137"/>
                    <measurement group_id="O5" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="120"/>
                    <measurement group_id="O5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="104"/>
                    <measurement group_id="O5" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 60%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>= 100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least 30 Percent (%) and 50% Reduction From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</title>
        <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least 30 Percent (%) and 50% Reduction From Baseline in Daily Average Low Back Pain Intensity (LBPI) Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)</title>
          <description>Daily average back pain was assessed on an 11-point numeric rating scale (NRS) captured through an interactive voice response system (IVRS). The participant described the chronic low back pain (CLBP) during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline value was calculated as mean of the scores over 5 days prior to randomization (initial pain assessment period). Post-baseline value was calculated as mean of the scores over the 7-day period prior to and including the post-baseline visit.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: &gt;=30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4"/>
                    <measurement group_id="O2" value="32.8"/>
                    <measurement group_id="O3" value="42.4"/>
                    <measurement group_id="O4" value="41.0"/>
                    <measurement group_id="O5" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: &gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="19.3"/>
                    <measurement group_id="O4" value="22.0"/>
                    <measurement group_id="O5" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: &gt;=30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="43.5"/>
                    <measurement group_id="O3" value="54.2"/>
                    <measurement group_id="O4" value="52.5"/>
                    <measurement group_id="O5" value="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: &gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="35.6"/>
                    <measurement group_id="O4" value="35.9"/>
                    <measurement group_id="O5" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: &gt;=30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="43.1"/>
                    <measurement group_id="O3" value="48.1"/>
                    <measurement group_id="O4" value="50.8"/>
                    <measurement group_id="O5" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: &gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="25.4"/>
                    <measurement group_id="O3" value="32.5"/>
                    <measurement group_id="O4" value="35.3"/>
                    <measurement group_id="O5" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: &gt;=30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="42.7"/>
                    <measurement group_id="O3" value="48.1"/>
                    <measurement group_id="O4" value="50.5"/>
                    <measurement group_id="O5" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: &gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="36.3"/>
                    <measurement group_id="O4" value="40.0"/>
                    <measurement group_id="O5" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="35.8"/>
                    <measurement group_id="O3" value="41.7"/>
                    <measurement group_id="O4" value="46.4"/>
                    <measurement group_id="O5" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="25.4"/>
                    <measurement group_id="O3" value="31.9"/>
                    <measurement group_id="O4" value="35.3"/>
                    <measurement group_id="O5" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Worst and Average Pain at Week 2, 4, 8, 12, 16: Baseline Observation Carried Forward (BOCF)</title>
        <description>BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure level of interference of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes). Results are reported for worst and average pain, each with a score range: 0 (no pain) and 10 (pain as bad as you can imagine), higher scores indicated worse pain.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Worst and Average Pain at Week 2, 4, 8, 12, 16: Baseline Observation Carried Forward (BOCF)</title>
          <description>BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure level of interference of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes). Results are reported for worst and average pain, each with a score range: 0 (no pain) and 10 (pain as bad as you can imagine), higher scores indicated worse pain.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.27" spread="1.51"/>
                    <measurement group_id="O2" value="7.10" spread="1.53"/>
                    <measurement group_id="O3" value="7.04" spread="1.49"/>
                    <measurement group_id="O4" value="7.36" spread="1.59"/>
                    <measurement group_id="O5" value="7.28" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="1.44"/>
                    <measurement group_id="O2" value="6.25" spread="1.51"/>
                    <measurement group_id="O3" value="6.08" spread="1.52"/>
                    <measurement group_id="O4" value="6.35" spread="1.45"/>
                    <measurement group_id="O5" value="6.27" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="2.33"/>
                    <measurement group_id="O2" value="-1.76" spread="2.14"/>
                    <measurement group_id="O3" value="-2.19" spread="2.41"/>
                    <measurement group_id="O4" value="-2.08" spread="2.60"/>
                    <measurement group_id="O5" value="-1.97" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.93"/>
                    <measurement group_id="O2" value="-1.43" spread="1.91"/>
                    <measurement group_id="O3" value="-1.69" spread="2.11"/>
                    <measurement group_id="O4" value="-1.65" spread="2.34"/>
                    <measurement group_id="O5" value="-1.57" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="2.38"/>
                    <measurement group_id="O2" value="-2.21" spread="2.28"/>
                    <measurement group_id="O3" value="-2.57" spread="2.50"/>
                    <measurement group_id="O4" value="-2.88" spread="2.64"/>
                    <measurement group_id="O5" value="-2.16" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="1.95"/>
                    <measurement group_id="O2" value="-1.88" spread="1.91"/>
                    <measurement group_id="O3" value="-2.09" spread="2.18"/>
                    <measurement group_id="O4" value="-2.32" spread="2.34"/>
                    <measurement group_id="O5" value="-1.77" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="2.33"/>
                    <measurement group_id="O2" value="-1.94" spread="2.30"/>
                    <measurement group_id="O3" value="-2.35" spread="2.45"/>
                    <measurement group_id="O4" value="-2.55" spread="2.70"/>
                    <measurement group_id="O5" value="-1.98" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="1.93"/>
                    <measurement group_id="O2" value="-1.78" spread="1.99"/>
                    <measurement group_id="O3" value="-1.98" spread="2.18"/>
                    <measurement group_id="O4" value="-2.18" spread="2.42"/>
                    <measurement group_id="O5" value="-1.61" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="2.43"/>
                    <measurement group_id="O2" value="-1.99" spread="2.41"/>
                    <measurement group_id="O3" value="-2.53" spread="2.73"/>
                    <measurement group_id="O4" value="-2.70" spread="2.84"/>
                    <measurement group_id="O5" value="-2.13" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="2.12"/>
                    <measurement group_id="O2" value="-1.75" spread="2.11"/>
                    <measurement group_id="O3" value="-2.13" spread="2.35"/>
                    <measurement group_id="O4" value="-2.26" spread="2.54"/>
                    <measurement group_id="O5" value="-1.73" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Worst Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="2.35"/>
                    <measurement group_id="O2" value="-1.75" spread="2.34"/>
                    <measurement group_id="O3" value="-2.20" spread="2.66"/>
                    <measurement group_id="O4" value="-2.36" spread="2.78"/>
                    <measurement group_id="O5" value="-1.94" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="1.95"/>
                    <measurement group_id="O2" value="-1.58" spread="2.14"/>
                    <measurement group_id="O3" value="-1.89" spread="2.37"/>
                    <measurement group_id="O4" value="-2.03" spread="2.47"/>
                    <measurement group_id="O5" value="-1.66" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Pain Interference Index, Pain Interference Score for General Activity, Walking Ability, Sleep and Normal Work at Week 2, 4, 8, 12 and 16: BOCF</title>
        <description>BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure pain interference (PI) on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes); higher score = greater impairment. The 7 items in Q5 averaged to obtain pain interference index (function composite score), range: 0 (no interference) to 10 (complete interference); higher score = greater impairment.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) Score for Pain Interference Index, Pain Interference Score for General Activity, Walking Ability, Sleep and Normal Work at Week 2, 4, 8, 12 and 16: BOCF</title>
          <description>BPI-sf: self-report questionnaire rated on an 11-point scale, consists of 5 questions to assess severity and impact of pain on daily functions. Question 1-4 (Q1-Q4) measure severity of pain (worst, least, average, right now), each question ranging between 0 (no pain) to 10 (pain as bad as you can imagine). Question 5 (Q5) consists of 7 items which measure pain interference (PI) on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life), each item ranging from 0 (does not interfere) to 10 (completely interferes); higher score = greater impairment. The 7 items in Q5 averaged to obtain pain interference index (function composite score), range: 0 (no interference) to 10 (complete interference); higher score = greater impairment.</description>
          <population>ITT analysis set. BOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2: Pain Interference Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="2.20"/>
                    <measurement group_id="O2" value="-1.59" spread="2.14"/>
                    <measurement group_id="O3" value="-1.97" spread="2.33"/>
                    <measurement group_id="O4" value="-1.81" spread="2.63"/>
                    <measurement group_id="O5" value="-1.75" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Pain Interference Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="2.19"/>
                    <measurement group_id="O2" value="-1.99" spread="2.12"/>
                    <measurement group_id="O3" value="-2.40" spread="2.31"/>
                    <measurement group_id="O4" value="-2.63" spread="2.44"/>
                    <measurement group_id="O5" value="-2.01" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Pain Interference Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="2.19"/>
                    <measurement group_id="O2" value="-1.62" spread="2.21"/>
                    <measurement group_id="O3" value="-2.21" spread="2.47"/>
                    <measurement group_id="O4" value="-2.38" spread="2.60"/>
                    <measurement group_id="O5" value="-1.81" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Pain Interference Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="2.01"/>
                    <measurement group_id="O2" value="-1.52" spread="2.19"/>
                    <measurement group_id="O3" value="-2.02" spread="2.48"/>
                    <measurement group_id="O4" value="-2.17" spread="2.44"/>
                    <measurement group_id="O5" value="-1.59" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Pain Interference Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="2.20"/>
                    <measurement group_id="O2" value="-1.65" spread="2.16"/>
                    <measurement group_id="O3" value="-2.15" spread="2.34"/>
                    <measurement group_id="O4" value="-2.37" spread="2.45"/>
                    <measurement group_id="O5" value="-1.71" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: General Activity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="2.58"/>
                    <measurement group_id="O2" value="-1.72" spread="2.51"/>
                    <measurement group_id="O3" value="-2.20" spread="2.75"/>
                    <measurement group_id="O4" value="-2.06" spread="3.00"/>
                    <measurement group_id="O5" value="-1.92" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: General Activity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="2.55"/>
                    <measurement group_id="O2" value="-2.17" spread="2.42"/>
                    <measurement group_id="O3" value="-2.64" spread="2.59"/>
                    <measurement group_id="O4" value="-2.90" spread="2.84"/>
                    <measurement group_id="O5" value="-2.08" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: General Activity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="2.57"/>
                    <measurement group_id="O2" value="-1.70" spread="2.52"/>
                    <measurement group_id="O3" value="-2.27" spread="2.63"/>
                    <measurement group_id="O4" value="-2.53" spread="2.76"/>
                    <measurement group_id="O5" value="-1.77" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: General Activity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="2.54"/>
                    <measurement group_id="O2" value="-1.76" spread="2.54"/>
                    <measurement group_id="O3" value="-2.39" spread="2.73"/>
                    <measurement group_id="O4" value="-2.62" spread="2.87"/>
                    <measurement group_id="O5" value="-1.90" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: General Activity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="2.21"/>
                    <measurement group_id="O2" value="-1.68" spread="2.55"/>
                    <measurement group_id="O3" value="-2.20" spread="2.76"/>
                    <measurement group_id="O4" value="-2.26" spread="2.71"/>
                    <measurement group_id="O5" value="-1.65" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Walking Ability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="2.71"/>
                    <measurement group_id="O2" value="-1.59" spread="2.52"/>
                    <measurement group_id="O3" value="-1.83" spread="2.69"/>
                    <measurement group_id="O4" value="-1.81" spread="2.94"/>
                    <measurement group_id="O5" value="-1.73" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Walking Ability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="2.71"/>
                    <measurement group_id="O2" value="-1.91" spread="2.59"/>
                    <measurement group_id="O3" value="-2.32" spread="2.59"/>
                    <measurement group_id="O4" value="-2.58" spread="2.88"/>
                    <measurement group_id="O5" value="-2.00" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Walking Ability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="2.56"/>
                    <measurement group_id="O2" value="-1.62" spread="2.47"/>
                    <measurement group_id="O3" value="-2.01" spread="2.66"/>
                    <measurement group_id="O4" value="-2.36" spread="2.88"/>
                    <measurement group_id="O5" value="-1.72" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Walking Ability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="2.41"/>
                    <measurement group_id="O2" value="-1.63" spread="2.50"/>
                    <measurement group_id="O3" value="-2.13" spread="2.68"/>
                    <measurement group_id="O4" value="-2.34" spread="2.82"/>
                    <measurement group_id="O5" value="-1.80" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Walking Ability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="2.16"/>
                    <measurement group_id="O2" value="-1.49" spread="2.29"/>
                    <measurement group_id="O3" value="-1.91" spread="2.71"/>
                    <measurement group_id="O4" value="-2.14" spread="2.72"/>
                    <measurement group_id="O5" value="-1.53" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Normal Work</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="2.37"/>
                    <measurement group_id="O2" value="-1.75" spread="2.57"/>
                    <measurement group_id="O3" value="-2.01" spread="2.61"/>
                    <measurement group_id="O4" value="-2.01" spread="2.90"/>
                    <measurement group_id="O5" value="-1.67" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Normal Work</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="2.36"/>
                    <measurement group_id="O2" value="-2.03" spread="2.49"/>
                    <measurement group_id="O3" value="-2.49" spread="2.57"/>
                    <measurement group_id="O4" value="-2.79" spread="2.75"/>
                    <measurement group_id="O5" value="-2.03" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Normal Work</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="2.35"/>
                    <measurement group_id="O2" value="-1.72" spread="2.46"/>
                    <measurement group_id="O3" value="-2.25" spread="2.64"/>
                    <measurement group_id="O4" value="-2.58" spread="2.75"/>
                    <measurement group_id="O5" value="-1.76" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Normal Work</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="2.25"/>
                    <measurement group_id="O2" value="-1.76" spread="2.43"/>
                    <measurement group_id="O3" value="-2.35" spread="2.75"/>
                    <measurement group_id="O4" value="-2.57" spread="2.85"/>
                    <measurement group_id="O5" value="-1.85" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Normal Work</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="2.15"/>
                    <measurement group_id="O2" value="-1.55" spread="2.45"/>
                    <measurement group_id="O3" value="-2.09" spread="2.74"/>
                    <measurement group_id="O4" value="-2.40" spread="2.76"/>
                    <measurement group_id="O5" value="-1.65" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2: Pain Interference with Sleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.72"/>
                    <measurement group_id="O2" value="-1.7" spread="2.58"/>
                    <measurement group_id="O3" value="-2.0" spread="2.89"/>
                    <measurement group_id="O4" value="-1.7" spread="3.09"/>
                    <measurement group_id="O5" value="-2.2" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4: Pain Interference with Sleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.52"/>
                    <measurement group_id="O2" value="-2.3" spread="2.62"/>
                    <measurement group_id="O3" value="-2.6" spread="2.87"/>
                    <measurement group_id="O4" value="-2.7" spread="2.89"/>
                    <measurement group_id="O5" value="-2.2" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Pain Interference with Sleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.54"/>
                    <measurement group_id="O2" value="-1.9" spread="2.62"/>
                    <measurement group_id="O3" value="-2.4" spread="2.86"/>
                    <measurement group_id="O4" value="-2.4" spread="2.83"/>
                    <measurement group_id="O5" value="-1.9" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Pain Interference with Sleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.49"/>
                    <measurement group_id="O2" value="-1.8" spread="2.69"/>
                    <measurement group_id="O3" value="-2.4" spread="3.04"/>
                    <measurement group_id="O4" value="-2.5" spread="3.00"/>
                    <measurement group_id="O5" value="-2.0" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Pain Interference with Sleep</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.29"/>
                    <measurement group_id="O2" value="-1.7" spread="2.66"/>
                    <measurement group_id="O3" value="-2.3" spread="3.04"/>
                    <measurement group_id="O4" value="-2.3" spread="2.82"/>
                    <measurement group_id="O5" value="-1.8" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation Due to Lack of Efficacy</title>
        <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
        <time_frame>Baseline up to Week 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation Due to Lack of Efficacy</title>
          <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and full range cannot be estimated due to less number of participants with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and full range cannot be estimated due to less number of participants with events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Median and full range cannot be estimated due to less number of participants with events.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and full range cannot be estimated due to less number of participants with events.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median and full range cannot be estimated due to less number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic Low Back Pain (CLBP) Responder Index: Baseline Observation Carried Forward (BOCF)</title>
        <description>Chronic Low Back Pain (CLBP) Responder Index: A response was defined as reduction of at least 30% in mean daily average LBPI from baseline to a specified week, decrease of at least 30% in PGA of low back pain from baseline to the specified week and no worsening (increase) in RMDQ total score from baseline to the specified week. Participants who were responders were reported.</description>
        <time_frame>Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic Low Back Pain (CLBP) Responder Index: Baseline Observation Carried Forward (BOCF)</title>
          <description>Chronic Low Back Pain (CLBP) Responder Index: A response was defined as reduction of at least 30% in mean daily average LBPI from baseline to a specified week, decrease of at least 30% in PGA of low back pain from baseline to the specified week and no worsening (increase) in RMDQ total score from baseline to the specified week. Participants who were responders were reported.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. BOCF method was used to impute missing values.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="113"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="103"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="105"/>
                    <measurement group_id="O5" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) at Week 8 and 16</title>
        <description>WPAI:SHP is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Four scores are derived as percent: activity impairment (AI), impairment while working (IW), overall work impairment (OWI), work time missed (WTM). Each of 4 scores expressed as impairment percentages with a total possible score range of 0 to 100, high percentage= more impairment, less productivity.</description>
        <time_frame>Baseline, Week 8, 16</time_frame>
        <population>ITT analysis set. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP) at Week 8 and 16</title>
          <description>WPAI:SHP is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Four scores are derived as percent: activity impairment (AI), impairment while working (IW), overall work impairment (OWI), work time missed (WTM). Each of 4 scores expressed as impairment percentages with a total possible score range of 0 to 100, high percentage= more impairment, less productivity.</description>
          <population>ITT analysis set. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Activity Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="229"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.77" spread="22.88"/>
                    <measurement group_id="O2" value="55.15" spread="22.63"/>
                    <measurement group_id="O3" value="59.32" spread="21.48"/>
                    <measurement group_id="O4" value="60.81" spread="20.74"/>
                    <measurement group_id="O5" value="59.97" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Impairment While Working</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="142"/>
                    <count group_id="O4" value="158"/>
                    <count group_id="O5" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.19" spread="24.85"/>
                    <measurement group_id="O2" value="45.17" spread="23.51"/>
                    <measurement group_id="O3" value="49.15" spread="22.11"/>
                    <measurement group_id="O4" value="49.62" spread="26.01"/>
                    <measurement group_id="O5" value="48.90" spread="24.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Overall Work Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" spread="21.06"/>
                    <measurement group_id="O2" value="6.68" spread="21.61"/>
                    <measurement group_id="O3" value="7.51" spread="21.18"/>
                    <measurement group_id="O4" value="10.71" spread="26.29"/>
                    <measurement group_id="O5" value="8.30" spread="23.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Work Time Missed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="8.69"/>
                    <measurement group_id="O2" value="3.17" spread="12.03"/>
                    <measurement group_id="O3" value="2.02" spread="7.22"/>
                    <measurement group_id="O4" value="3.82" spread="11.50"/>
                    <measurement group_id="O5" value="3.26" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Activity Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="188"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="236"/>
                    <count group_id="O5" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.58" spread="24.31"/>
                    <measurement group_id="O2" value="-15.80" spread="25.16"/>
                    <measurement group_id="O3" value="-24.96" spread="26.32"/>
                    <measurement group_id="O4" value="-27.08" spread="28.65"/>
                    <measurement group_id="O5" value="-18.53" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Impairment While Working</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="106"/>
                    <count group_id="O4" value="114"/>
                    <count group_id="O5" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.79" spread="24.79"/>
                    <measurement group_id="O2" value="-10.75" spread="25.42"/>
                    <measurement group_id="O3" value="-21.98" spread="25.54"/>
                    <measurement group_id="O4" value="-19.21" spread="45.39"/>
                    <measurement group_id="O5" value="-16.70" spread="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Overall Work Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="245"/>
                    <count group_id="O4" value="241"/>
                    <count group_id="O5" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="21.56"/>
                    <measurement group_id="O2" value="0.08" spread="19.74"/>
                    <measurement group_id="O3" value="-3.83" spread="22.24"/>
                    <measurement group_id="O4" value="-6.64" spread="24.52"/>
                    <measurement group_id="O5" value="-4.58" spread="20.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8: Work Time Missed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="245"/>
                    <count group_id="O4" value="241"/>
                    <count group_id="O5" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="8.78"/>
                    <measurement group_id="O2" value="0.16" spread="9.53"/>
                    <measurement group_id="O3" value="-0.38" spread="9.12"/>
                    <measurement group_id="O4" value="-2.15" spread="12.35"/>
                    <measurement group_id="O5" value="-1.74" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Activity Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="146"/>
                    <count group_id="O3" value="188"/>
                    <count group_id="O4" value="190"/>
                    <count group_id="O5" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.50" spread="24.11"/>
                    <measurement group_id="O2" value="-19.45" spread="25.51"/>
                    <measurement group_id="O3" value="-29.95" spread="27.08"/>
                    <measurement group_id="O4" value="-31.79" spread="25.78"/>
                    <measurement group_id="O5" value="-24.28" spread="24.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16: Impairment While Working</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.60" spread="22.56"/>
                    <measurement group_id="O2" value="-15.22" spread="24.05"/>
                    <measurement group_id="O3" value="-27.65" spread="26.17"/>
                    <measurement group_id="O4" value="-24.57" spread="26.34"/>
                    <measurement group_id="O5" value="-21.05" spread="24.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16:Overall Work Impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="193"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" spread="14.15"/>
                    <measurement group_id="O2" value="-1.72" spread="15.37"/>
                    <measurement group_id="O3" value="-3.92" spread="24.38"/>
                    <measurement group_id="O4" value="-7.71" spread="24.10"/>
                    <measurement group_id="O5" value="-6.68" spread="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16:Work Time Missed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="193"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="6.67"/>
                    <measurement group_id="O2" value="-0.09" spread="7.49"/>
                    <measurement group_id="O3" value="-0.24" spread="11.20"/>
                    <measurement group_id="O4" value="-2.98" spread="10.69"/>
                    <measurement group_id="O5" value="-2.30" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Used Rescue Medications</title>
        <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
        <time_frame>Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set. LOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Used Rescue Medications</title>
          <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
          <population>ITT analysis set. LOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="292"/>
                <count group_id="O5" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="290"/>
                    <count group_id="O5" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3"/>
                    <measurement group_id="O2" value="69.7"/>
                    <measurement group_id="O3" value="74.1"/>
                    <measurement group_id="O4" value="73.4"/>
                    <measurement group_id="O5" value="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="53.9"/>
                    <measurement group_id="O3" value="54.3"/>
                    <measurement group_id="O4" value="53.4"/>
                    <measurement group_id="O5" value="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8"/>
                    <measurement group_id="O2" value="49.6"/>
                    <measurement group_id="O3" value="50.9"/>
                    <measurement group_id="O4" value="47.6"/>
                    <measurement group_id="O5" value="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                    <measurement group_id="O2" value="40.5"/>
                    <measurement group_id="O3" value="45.1"/>
                    <measurement group_id="O4" value="38.7"/>
                    <measurement group_id="O5" value="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="43.0"/>
                    <measurement group_id="O4" value="38.0"/>
                    <measurement group_id="O5" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Rescue Medication Use</title>
        <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
        <time_frame>Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set. LOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Rescue Medication Use</title>
          <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
          <population>ITT analysis set. LOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
          <units>days/week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="292"/>
                <count group_id="O5" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="290"/>
                    <count group_id="O5" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Rescue Medication Taken</title>
        <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
        <time_frame>Week 2, 4, 8, 12, 16</time_frame>
        <population>ITT analysis set. LOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Rescue Medication Taken</title>
          <description>In case of inadequate pain relief for CLBP or for non-CLBP related pain, acetaminophen up to 3000 mg per day up to 3 days per week could be taken as rescue medication.</description>
          <population>ITT analysis set. LOCF method was used to impute missing values. Here, &quot;Overall number of participants analyzed&quot; signifies those participants who were evaluable for this outcome measure and 'Number Analyzed' signifies those participants who were evaluable for this outcome measure at given time points for each group, respectively.</population>
          <units>mg per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="292"/>
                <count group_id="O5" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="290"/>
                    <count group_id="O5" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4168.12" spread="4708.74"/>
                    <measurement group_id="O2" value="4305.19" spread="5102.74"/>
                    <measurement group_id="O3" value="3952.22" spread="4527.82"/>
                    <measurement group_id="O4" value="4306.90" spread="4880.47"/>
                    <measurement group_id="O5" value="3350.52" spread="4564.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3547.83" spread="4860.04"/>
                    <measurement group_id="O2" value="3252.16" spread="5189.48"/>
                    <measurement group_id="O3" value="2583.62" spread="3966.56"/>
                    <measurement group_id="O4" value="2688.36" spread="4314.58"/>
                    <measurement group_id="O5" value="2680.89" spread="4120.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2910.87" spread="4483.80"/>
                    <measurement group_id="O2" value="2633.62" spread="4309.14"/>
                    <measurement group_id="O3" value="2829.35" spread="4458.51"/>
                    <measurement group_id="O4" value="2558.22" spread="4232.71"/>
                    <measurement group_id="O5" value="2477.89" spread="4270.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2619.57" spread="5350.37"/>
                    <measurement group_id="O2" value="2256.47" spread="4350.69"/>
                    <measurement group_id="O3" value="2511.95" spread="4164.31"/>
                    <measurement group_id="O4" value="2351.03" spread="4297.87"/>
                    <measurement group_id="O5" value="2455.78" spread="4580.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="293"/>
                    <count group_id="O4" value="292"/>
                    <count group_id="O5" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2523.91" spread="4493.14"/>
                    <measurement group_id="O2" value="2140.09" spread="4167.33"/>
                    <measurement group_id="O3" value="2250.85" spread="3979.75"/>
                    <measurement group_id="O4" value="2369.86" spread="4417.07"/>
                    <measurement group_id="O5" value="2448.98" spread="4677.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Neuropathy Impairment Score (NIS) at Week 8, 16 and 24</title>
        <description>NIS is a standardized instrument used to evaluate signs of peripheral neuropathy in participants. NIS is the sum of scores of 37 items, from both the left and right side of following 4 domains: cranial nerves (5 items), muscle weakness (19 items), reflexes (5 items) and sensation (8 items). Each of 24 items related to cranial nerves and muscle weakness, scored from 0 (normal) to 4 (paralysis); higher scores indicated higher abnormality/impairment. Each of 13 items related to reflexes and sensation, scored as 0 (normal), 1 (decreased) and 2 (absent); higher scores indicated lesser reflexes and sensation. For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.</description>
        <time_frame>Baseline, Week 8, 16, 24</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Neuropathy Impairment Score (NIS) at Week 8, 16 and 24</title>
          <description>NIS is a standardized instrument used to evaluate signs of peripheral neuropathy in participants. NIS is the sum of scores of 37 items, from both the left and right side of following 4 domains: cranial nerves (5 items), muscle weakness (19 items), reflexes (5 items) and sensation (8 items). Each of 24 items related to cranial nerves and muscle weakness, scored from 0 (normal) to 4 (paralysis); higher scores indicated higher abnormality/impairment. Each of 13 items related to reflexes and sensation, scored as 0 (normal), 1 (decreased) and 2 (absent); higher scores indicated lesser reflexes and sensation. For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="295"/>
                    <count group_id="O4" value="295"/>
                    <count group_id="O5" value="295"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="2.68"/>
                    <measurement group_id="O2" value="1.16" spread="3.04"/>
                    <measurement group_id="O3" value="1.03" spread="2.79"/>
                    <measurement group_id="O4" value="1.31" spread="4.75"/>
                    <measurement group_id="O5" value="1.02" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="194"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="240"/>
                    <count group_id="O5" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.43"/>
                    <measurement group_id="O2" value="-0.41" spread="2.79"/>
                    <measurement group_id="O3" value="-0.09" spread="1.49"/>
                    <measurement group_id="O4" value="-0.38" spread="3.61"/>
                    <measurement group_id="O5" value="-0.06" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="128"/>
                    <count group_id="O2" value="150"/>
                    <count group_id="O3" value="194"/>
                    <count group_id="O4" value="192"/>
                    <count group_id="O5" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="1.67"/>
                    <measurement group_id="O2" value="-0.27" spread="1.96"/>
                    <measurement group_id="O3" value="0.05" spread="1.36"/>
                    <measurement group_id="O4" value="0.02" spread="1.63"/>
                    <measurement group_id="O5" value="-0.18" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="3.47"/>
                    <measurement group_id="O2" value="-0.15" spread="1.09"/>
                    <measurement group_id="O3" value="0.10" spread="1.04"/>
                    <measurement group_id="O4" value="-0.46" spread="1.22"/>
                    <measurement group_id="O5" value="-0.48" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Anti-Tanezumab Antibodies</title>
        <description>Human serum anti-drug antibody (ADA) samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative enzyme-linked immunosorbent assay (ELISA). Same participant may have positive ADA result at more than 1 time point.</description>
        <time_frame>Baseline (Day 1), Week 8, 16, 24</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Anti-Tanezumab Antibodies</title>
          <description>Human serum anti-drug antibody (ADA) samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative enzyme-linked immunosorbent assay (ELISA). Same participant may have positive ADA result at more than 1 time point.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="289"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="204"/>
                    <count group_id="O3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Tanezumab</title>
        <description>Analysis was done by setting concentration values below the lower limit of quantification (LLOQ) to zero.</description>
        <time_frame>Baseline (pre-dose and 1 hour [hr] post-dose); Any time point at Week 4 Visit; Week 8 (pre-dose and 1 hr post-dose); Any time point at Week 16 Visit, at Week 24 Visit</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Tanezumab</title>
          <description>Analysis was done by setting concentration values below the lower limit of quantification (LLOQ) to zero.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively</population>
          <units>nanogram per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="288"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7627" spread="315.3581"/>
                    <measurement group_id="O2" value="60.2354" spread="383.8924"/>
                    <measurement group_id="O3" value="40.9396" spread="317.3858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1 hr post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1944.46" spread="572.9289"/>
                    <measurement group_id="O2" value="4105.46" spread="1495.906"/>
                    <measurement group_id="O3" value="8460.14" spread="2983.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472.248" spread="238.5394"/>
                    <measurement group_id="O2" value="983.377" spread="346.1361"/>
                    <measurement group_id="O3" value="1983.72" spread="598.7860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.405" spread="333.2990"/>
                    <measurement group_id="O2" value="442.843" spread="208.6190"/>
                    <measurement group_id="O3" value="1081.69" spread="997.0692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: 1 hr post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2026.01" spread="693.5790"/>
                    <measurement group_id="O2" value="4637.82" spread="2630.921"/>
                    <measurement group_id="O3" value="9161.84" spread="4274.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="174"/>
                    <count group_id="O3" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.804" spread="245.3006"/>
                    <measurement group_id="O2" value="531.014" spread="256.1994"/>
                    <measurement group_id="O3" value="1393.40" spread="1219.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.991" spread="402.0603"/>
                    <measurement group_id="O2" value="636.217" spread="567.9855"/>
                    <measurement group_id="O3" value="1222.17" spread="1105.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Nerve Growth Factor (NGF) Concentration</title>
        <time_frame>Baseline (pre-dose and 1 hour [hr] post-dose); Any time point at Week 4 Visit; Week 8 (pre-dose and 1 hr post-dose); Any time point at Week 16 Visit, at Week 24 Visit</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Nerve Growth Factor (NGF) Concentration</title>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication. Here, &quot;Overall number of participants analyzed&quot; = participants who were evaluable for this outcome measure and 'Number Analyzed' = participants who were evaluable for this outcome measure at given time points for each group, respectively</population>
          <units>picogram per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="277"/>
                <count group_id="O4" value="268"/>
                <count group_id="O5" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="277"/>
                    <count group_id="O4" value="268"/>
                    <count group_id="O5" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.65" spread="11.68"/>
                    <measurement group_id="O2" value="44.38" spread="49.12"/>
                    <measurement group_id="O3" value="55.66" spread="202.0"/>
                    <measurement group_id="O4" value="61.79" spread="220.7"/>
                    <measurement group_id="O5" value="35.50" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1 hr post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="166"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="197"/>
                    <count group_id="O5" value="205"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.90" spread="11.99"/>
                    <measurement group_id="O2" value="96.76" spread="35.08"/>
                    <measurement group_id="O3" value="113.33" spread="251.5"/>
                    <measurement group_id="O4" value="126.50" spread="192.8"/>
                    <measurement group_id="O5" value="40.30" spread="13.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="187"/>
                    <count group_id="O3" value="228"/>
                    <count group_id="O4" value="231"/>
                    <count group_id="O5" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.33" spread="655.1"/>
                    <measurement group_id="O2" value="3217.6" spread="1134"/>
                    <measurement group_id="O3" value="3981.7" spread="1362"/>
                    <measurement group_id="O4" value="4456.7" spread="1325"/>
                    <measurement group_id="O5" value="38.17" spread="16.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="173"/>
                    <count group_id="O3" value="208"/>
                    <count group_id="O4" value="212"/>
                    <count group_id="O5" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.66" spread="707.6"/>
                    <measurement group_id="O2" value="2671.7" spread="1249"/>
                    <measurement group_id="O3" value="3624.7" spread="1398"/>
                    <measurement group_id="O4" value="4238.6" spread="1604"/>
                    <measurement group_id="O5" value="41.47" spread="80.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: 1 hr post-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="196"/>
                    <count group_id="O4" value="196"/>
                    <count group_id="O5" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.71" spread="750.3"/>
                    <measurement group_id="O2" value="2943.5" spread="1334"/>
                    <measurement group_id="O3" value="3950.9" spread="1479"/>
                    <measurement group_id="O4" value="4929.1" spread="1775"/>
                    <measurement group_id="O5" value="69.74" spread="241.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="170"/>
                    <count group_id="O4" value="171"/>
                    <count group_id="O5" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.96" spread="23.56"/>
                    <measurement group_id="O2" value="3263.0" spread="1539"/>
                    <measurement group_id="O3" value="4490.5" spread="1953"/>
                    <measurement group_id="O4" value="5842.2" spread="2377"/>
                    <measurement group_id="O5" value="135.17" spread="810.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="83"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.61" spread="916.4"/>
                    <measurement group_id="O2" value="2602.0" spread="1486"/>
                    <measurement group_id="O3" value="3549.5" spread="1747"/>
                    <measurement group_id="O4" value="4420.3" spread="1776"/>
                    <measurement group_id="O5" value="38.77" spread="15.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 24 that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 20 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
          </group>
          <group group_id="O5">
            <title>Naproxen 500 mg</title>
            <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 24 that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
          <population>ITT analysis set included all participants who received at least 1 dose of intravenous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="295"/>
                <count group_id="O4" value="295"/>
                <count group_id="O5" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="171"/>
                    <measurement group_id="O4" value="190"/>
                    <measurement group_id="O5" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="E2">
          <title>Tanezumab 5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 milligram (mg) intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="E3">
          <title>Tanezumab 10 mg</title>
          <description>Tanezumab (RN624 or PF-04383119)10 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="E4">
          <title>Tanezumab 20 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 20 mg intravenous infusion over a 5-minute period at Day 1 and Week 8 along with placebo matched to naproxen tablet orally twice daily up to Week 16.</description>
        </group>
        <group group_id="E5">
          <title>Naproxen 500 mg</title>
          <description>Naproxen 500 mg tablet orally twice daily up to Week 16 along with placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion over a 5-minute period at Day 1 and Week 8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="114" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="134" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="295"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results for total duration of response as defined by days with a &gt;=30% and a &gt;=50% reduction from baseline in the daily average LBPI NRS score was not reported due changed in planned analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

